Patients at intermediate risk of developing cardiovascular disease (CVD)
present their physicians with a vexing question: Should these patients—those
who have a 10% to 20% chance of developing coronary heart disease over the
next 10 years—try to avoid CVD through lifestyle modifications, or are
more aggressive medical therapies warranted?
That question prompts another one: How should physicians determine appropriate
interventions for such patients? Should they rely on the Framingham Heart
Study Prediction Score, or couple that information with further evaluations,
such as imaging and exercise testing?
Mitka M. Panel Endorses Limited Role for CRP Tests. JAMA. 2003;289(8):973-974. doi:10.1001/jama.289.8.973